Notably, this combination was strongly synergistic in p53 mutant PCa cells, which suggests that this novel therapeutic approach might exhibit an improved selective advantage in metastatic PCa cells harboring mutant p53s. The gene discussed is TP53; the disease is posterior cortical atrophy.